NasdaqCM:NEOHealthcare
Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment?
In June 2026, NeoGenomics, Inc. announced it had appointed Carolyn Starrett, former Flatiron Health CEO and experienced healthcare data and AI leader, to its Board of Directors.
Her background in applying AI and real-world data to cancer care and drug development could meaningfully influence how NeoGenomics develops and commercializes its oncology testing and digital solutions.
We’ll now examine how Starrett’s AI and data-driven oncology expertise may influence NeoGenomics’ existing...